Sodium Deoxycholate for Submental Contouring.
The chin and jaw line are integral parts of an individual's aesthetic profile, and the presence of submental fat detracts from this and can lead to displeasure with one's facial appearance. While liposuction and cosmetic surgery are regarded as the gold standard in treating submental fat, surgical intervention is not appealing to all patients and has potential surgical complications including longer recovery, and contour irregularities. Despite ample advances in aesthetic medicine to enhance the appearance of the face, very little is available in non-invasive options to reduce submental fat that has been supported by robust evidence. ATX-101, a proprietary formulation of deoxycholic acid that is synthetically derived, has been extensively explored in a vigorous clinical development program that has established the safety and efficacy of the injectable. It has recently received approval by regulatory authorities in Canada (Belkyra™) and the US (Kybella®) for the treatment of submental fat.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
S
S
Humphrey
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
K
K
Beleznay
Department of Ophthalmology and Visual Science, University of British Columbia, Vancouver, BC, Canada.
J D A
JD
Beleznay
D002680:Chin; D017326:Clinical Trials, Phase III as Topic; D003357:Cosmetic Techniques; D003840:Deoxycholic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents; D006801:Humans; D007279:Injections, Subcutaneous; D050151:Subcutaneous Fat / Q000187:drug effects*
C000599116:ATX-101 compound; D003879:Dermatologic Agents; D003840:Deoxycholic Acid